Analysis of stage IVB endometrial carcinoma patients with distant metastasis: a review of prognoses in 55 patients.
BACKGROUND
Adequate treatment for extremely advanced endometrial cancer is unknown. The purpose of this study was to clarify the prognosis of patients with stage IVB endometrial carcinoma and the validity of treatment. Furthermore, we evaluated whether there was a connection between the prognosis and the site of metastasis.


METHODS
The prognoses of 55 patients with stage IVB endometrial carcinoma were studied with reference to the initial treatment method and the metastatic site at the time of the initial treatment.


RESULTS
The median survivals of the group of 35 patients who were initially treated with surgery and the group of 10 patients who underwent radiotherapy or chemotherapy as their initial treatment followed by surgery were 11.5 months and 9.5 months, respectively. The residual tumor diameter after surgery was precisely measured in 40 of these 45 patients. The prognosis was significantly better in the patients with a residual tumor diameter of less than 2 cm compared to those with a tumor diameter of 2 cm or greater, and the median survival periods in these two groups were 23.5 months and 11.5 months, respectively (P = 0.027). Furthermore, the prognosis of patients with lung metastasis was significantly better than that of patients with non-lung hematogenous metastasis; the median survival periods of these two groups were 18.5 months and 10.5 months, respectively (P = 0.014).


CONCLUSIONS
For operable patients, surgery as an initial treatment and reduction of the residual tumor size to less than 2 cm appeared to contribute to a better prognosis. In addition, conservative initial treatment and the presence of non-lung hematogenous metastasis were poor prognostic factors.
Numazaki
Reiko
R
Department of Gynecology, Kanagawa Cancer Center Hospital, Yokohama, Japan.
Miyagi
Etsuko
E
Konnai
Katsuyuki
K
Ikeda
Masae
M
Yamamoto
Akihito
A
Onose
Ryo
R
Kato
Hisamori
H
Okamoto
Naoyuki
N
Hirahara
Fumiki
F
Nakayama
Hiroki
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D005260:Female; D013509:Gynecologic Surgical Procedures; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
Gynecol Oncol. 1984 Jan;17(1):75-84
6693054
Cancer. 2004 Jan 1;100(1):89-96
14692028
CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1
10200775
Gynecol Oncol. 1995 Jan;56(1):34-8
7821845
Gynecol Oncol. 1999 Jun;73(3):461-3
10366480
Cancer. 1987 Oct 15;60(8):1737-40
3115558
AJR Am J Roentgenol. 1976 Jan;126(1):148-54
175674
Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1915-23
4055452
Gynecol Oncol. 1992 May;45(2):142-6
1592280
Cancer Chemother Rep. 1966 Mar;50(3):163-70
5910392
Gynecol Oncol. 2000 Aug;78(2):85-91
10926785
Gynecol Oncol. 1997 Oct;67(1):56-60
9345357
Gynecol Oncol. 1994 Dec;55(3 Pt 1):363-7
7835775
Obstet Gynecol. 1992 Aug;80(2):204-8
1635733
Gynecol Oncol. 1990 Aug;38(2):210-5
2387538
Gynecol Oncol. 1994 Feb;52(2):237-40
8314145